Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcifications (PYROCALM)

Centre Hospitalier Universitaire de Nice

Status: Enrolling

Conditions: Liver Cirrhosis

Treatments: Other: a blood test and urine sample collection.

Study type: Interventional

Funder types: Other

Identifiers

NCT07201649

24-PP-15

Details and patient eligibility

About

Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE). We showed decrease plams level of PPi in patients with liver cirrhosis. We hypothezised that liver transplant should block AC and restore PPi plasma level.

Enrollment: 95 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• everyone requiring liver transplantation for the treatment of a chronic liver disease

Exclusion criteria

• MELD score >25, viral replication

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

95 participants in 1 patient group

Patients eligible for Hepatit Transplantation

Other group

Description:

Patients eligible for HT are contacted by a clinical research coordinator, and if they agree, an inclusion visit is arranged. HT takes place according to transplant availability. As soon as the patient is able to return home after HT, a visit is organised, defining the T1 period. A visit is carried out 120 days after HT and the end-of-study visit is scheduled to define the T2 period, which is the same length as the T1 period for each patient.

Treatment:

Other: a blood test and urine sample collection.